Advances in targeted therapy for unresectable melanoma: New drugs and combinations

被引：46

作者：

Hao, Mengze ^{[1
,2
]}

Song, Fengju ^{[2
,3
]}

Du, Xiaoling ^{[4
]}

Wang, Guowen ^{[1
,2
]}

Yang, Yun ^{[1
,2
]}

Chen, Kexin ^{[2
,3
]}

Yang, Jilong ^{[1
,2
]}

机构：

[1] Tianjin Med Univ, Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor, Tianjin 30060, Peoples R China

[2] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China

[3] Tianjin Med Univ, Canc Hosp & Inst, Dept Epidemiol & Biostat, Tianjin 300060, Peoples R China

[4] Tianjin Med Univ, Dept Diagnost, Tianjin 30060, Peoples R China

来源：

CANCER LETTERS | 2015年 / 359卷 / 01期

关键词：

BRAF; MEK; c-KIT; PI3K/Akt/mTOR; CTLA-4; PD-1/L1; PHASE-II TRIAL; OPEN-LABEL; METASTATIC MELANOMA; PLUS DACARBAZINE; DOSE-ESCALATION; 1ST-LINE TREATMENT; CANCER STATISTICS; WEEKLY PACLITAXEL; CLINICAL ACTIVITY; MEK INHIBITION;

D O I：

10.1016/j.canlet.2014.12.050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma is the most deadly cutaneous cancer primarily derived from melanocytes with a poor prognosis in advanced stage. The therapy regimen for early stage melanoma patients is surgical resection with adjuvant IFN-alpha-2b therapy. For metastatic lesions, standard chemotherapy such as dacarbazine (DTIC) has not achieved a satisfying response rate. Therefore, new approaches to manage this deadly disease are highly expected to enhance the cure rate and to extend clinical benefits to patients with unresectable melanoma. Fortunately, the targeted therapeutic drugs and immunotherapy such as vemurafenib, dabrafenib, ipilimumab, and trametinib have shown their special advantage in the treatment of advanced melanoma. This article is to overview the advances in targeted therapy for unresectable melanoma patients. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 8

页数：8

共 90 条

[1] Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib [J].

Acquaviva, Jaime ;

Smith, Donald L. ;

Jimenez, John-Paul ;

Zhang, Chaohua ;

Sequeira, Manuel ;

He, Suqin ;

Sang, Jim ;

Bates, Richard C. ;

Proia, David A. .

MOLECULAR CANCER THERAPEUTICS, 2014, 13 (02) :353-363

[2] Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies - Roles of anoikis [J].

Aixinjueluo, W ;

Furukawa, K ;

Zhang, Q ;

Hamamura, K ;

Tokuda, N ;

Yoshida, S ;

Ueda, R ;

Furukawa, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (33) :29828-29836

[3]

Algazi AP, 2013, J CLIN ONCOL, V31

[4] Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases [J].

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

McDermott, David F. ;

Kramer, Amy ;

Giles, Lydia ;

Gramlich, Kristi ;

Carberry, Mary ;

Troxel, Andrea B. ;

Letrero, Richard ;

Nathanson, Katherine L. ;

Atkins, Michael B. ;

O'Dwyer, Peter J. ;

Flaherty, Keith T. .

CLINICAL CANCER RESEARCH, 2009, 15 (24) :7711-7718

[5] A potential role for nilotinib in KIT-mutated melanoma [J].

An Tran ;

Tawbi, Hussein A. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (06) :861-869

[6]

Ascierto P. A., 2014, J CLON ONCOL S9102, V32

[7] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[8] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[9] The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer [J].

Banerji, Udai ;

Camidge, D. Ross ;

Verheul, Henk M. W. ;

Agarwal, Roshan ;

Sarker, Debashis ;

Kaye, Stan B. ;

Desar, Ingrid M. E. ;

Timmer-Bonte, Johanna N. H. ;

Eckhardt, S. Gail ;

Lewis, Karl D. ;

Brown, Kathryn H. ;

Cantarini, Mireille V. ;

Morris, Clive ;

George, Sarah M. A. ;

Smith, Paul D. ;

van Herpen, Carla M. L. .

CLINICAL CANCER RESEARCH, 2010, 16 (05) :1613-1623

[10] Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells [J].

Beck, Daniela ;

Niessner, Heike ;

Smalley, Keiran S. M. ;

Flaherty, Keith ;

Paraiso, Kim H. T. ;

Busch, Christian ;

Sinnberg, Tobias ;

Vasseur, Sophie ;

Iovanna, Juan Lucio ;

Driessen, Stefan ;

Stork, Bjoern ;

Wesselborg, Sebastian ;

Schaller, Martin ;

Biedermann, Tilo ;

Bauer, Juergen ;

Lasithiotakis, Konstantinos ;

Weide, Benjamin ;

Eberle, Juergen ;

Schittek, Birgit ;

Schadendorf, Dirk ;

Garbe, Claus ;

Kulms, Dagmar ;

Meier, Friedegund .

SCIENCE SIGNALING, 2013, 6 (260)

← 1 2 3 4 5 6 7 8 9 →